ADMA Biologics, Inc. (ADMA) — Financial statements
Income statement, balance sheet, and cash flow for ADMA Biologics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 510↑19.6% | 426↑65.2% | 258↑67.6% | 154↑90.4% | 81 | |
| Cost of Revenue | 217↑5.1% | 207↑22.2% | 169↑42.5% | 119↑48.9% | 80 | |
| Gross Profit | 293↑33.3% | 220↑146.8% | 89↑152.2% | 35↑2906.4% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 5↑162.7% | 2↓45.1% | 3↓8.7% | 4↓0.9% | 4 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 92↑23.5% | 74↑25.6% | 59↑12.5% | 52↑22.3% | 43 | |
| Other Expenses | 5↑7.5% | 5↓7.2% | 5↓73.1% | 19↑42.7% | 13 | |
| Operating Expenses | 101↑25.8% | 81↑19.7% | 67↓9.8% | 75↑25.3% | 60 | |
| Total Costs & Expenses | 319↑10.9% | 287↑21.5% | 237↑22.3% | 193↑38.9% | 139 | |
| Operating Results | ||||||
| Operating Income | 191↑37.7% | 139↑542.5% | 22↑155.0% | -39↑32.6% | -58 | |
| Depreciation & Amortization | 8↑0.6% | 8↓3.4% | 8↑17.1% | 7↑29.4% | 5 | |
| EBITDA | 198↑34.0% | 148↑2784.6% | 5↑113.0% | -40↑25.6% | -53 | |
| EBIT | 190↑35.9% | 140↑4447.6% | -3↑93.1% | -47↑20.4% | -59 | |
| Interest & Other Income | ||||||
| Net Interest Income | -5↑55.7% | -12↑49.5% | -23↓21.7% | -19↓47.7% | -13 | |
| Interest Income | 2↓10.8% | 2↑29.7% | 2↑3506.7% | 0.04↑29.8% | 0.03 | |
| Interest Expense | 7↓49.0% | 14↓44.3% | 25↑29.8% | 19↑47.7% | 13 | |
| Non-Operating Income | 2↑353.7% | -0.66↓102.7% | 25↑242.2% | 7↑3245.6% | 0.22 | |
| Other Income / Expenses | -9↑33.8% | -13↑73.4% | -50↓87.9% | -27↓99.9% | -13 | |
| Income Before Tax | 183↑45.3% | 126↑545.2% | -28↑57.2% | -66↑8.0% | -72 | |
| Income Tax Expense | 36↑149.6% | -72 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 147↓25.7% | 198↑800.0% | -28↑57.2% | -66↑8.0% | -72 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 147↓25.7% | 198↑800.0% | -28↑57.2% | -66↑8.0% | -72 | |
| Bottom-Line Net Income | 147↓25.7% | 198↑800.0% | -28↑57.2% | -66↑8.0% | -72 | |
| EPS (Basic) | 0.62↓27.1% | 0.85↑753.8% | -0.13↑69.8% | -0.43↑29.5% | -0.61 | |
| EPS (Diluted) | 0.60↓25.9% | 0.81↑723.1% | -0.13↑69.8% | -0.43↑29.5% | -0.61 | |
| Weighted Average Shares | 238↑2.2% | 233↑4.1% | 224↑13.2% | 198↑41.8% | 140 | |
| Weighted Average Diluted Shares | 245↑0.6% | 243↑8.6% | 224↑13.2% | 198↑41.8% | 140 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.